NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC) - Slamon, DJ; Fasching, PA; Patel, R (J Clin Oncol, 2019)
et al.